Summary

AI-generated

This summary is written by a language model reading the source document. It is not the publisher's words and is not a substitute for the original.

Learn more about AI enrichment

The Regionalized Vaccine Manufacturing Collaborative (RVMC) framework proposes a shift from global hub-and-spoke vaccine production to regionalized ecosystems. It outlines eight pillars—Business Archetypes, Healthy Markets, Financial Models, R&D and Manufacturing Innovation, Technology Transfer and Workforce Development, Supply Chain and Infrastructure, Product Regulation, and Policy and Governance—to enable coalitions of countries to achieve the scale necessary for viable production. The framework emphasizes the use of 'programmable vaccines' like mRNA to leapfrog older technologies and advocates for pooled regional demand to attract investment and ensure equitable access.

Key insights

AI-generated

These insights are written by a language model reading the source document. They are not the publisher's words and are not a substitute for the original.

Learn more about AI enrichment
  • The COVID-19 pandemic demonstrated a direct correlation between a region's access to vaccine development and production capacity and its vaccination rates; for instance, Africa imports over 99% of its vaccines and was 'last in the queue' for supply.
  • Regional investment in vaccine manufacturing, R&D, and regulation is more cost-effective than national-level investment, with World Bank analysis indicating cost-benefit ratios four times higher than national investments and costing less than 1% of total government health expenditure.
  • To achieve economic viability, regions should adopt diverse business archetypes, such as Contract Manufacturing Organizations (CMOs), Contract Development Manufacturing Organizations (CDMOs), biosimilars, or locally focused biopharma, rather than relying on a single model.
  • Pooled regional demand is essential to create scale efficiencies, increase negotiating power for volume discounts, and provide the predictable demand necessary to attract qualified suppliers and de-risk private investment.
  • The framework advocates for a 'reverse' R&D roadmap—moving from applied and translational innovation back to clinical and discovery research—to help new regions catch up with established international teams.
  • Programmable vaccine technologies, such as mRNA, offer regions an opportunity to 'leapfrog' older technologies, potentially reducing capital investment and speeding up the response to diseases of neglect.
  • Successful technology transfer requires more than just licensing; it necessitates customized training modules, learning management infrastructure, and ongoing facility-level support from the IP holder to ensure the local workforce can operate the technology.
  • Regional supply chains should be designed as a 'web of mutually dependent nodes' across member states to avoid the single-point-of-failure risks inherent in global hub-and-spoke models.
  • Harmonizing product regulation through joint review processes, mutual recognition, and shared submission procedures can reduce the time and cost for manufacturers to enter regional markets without compromising safety.
  • Financial sustainability for new facilities often requires a roughly 50/50 split between the capital needed to build the facility and the funding required to support market uptake until the operation becomes self-sustaining.

Cite the original document

APA
World Economic Forum (2024). Regionalized Vaccine Manufacturing Collaborative. https://www3.weforum.org/docs/WEF_Regionalized_Vaccine_Manufacturing_Collaborative_2024.pdf
Chicago
World Economic Forum. Regionalized Vaccine Manufacturing Collaborative. 2024. https://www3.weforum.org/docs/WEF_Regionalized_Vaccine_Manufacturing_Collaborative_2024.pdf.
Wikipedia
{{cite report |author=World Economic Forum |title=Regionalized Vaccine Manufacturing Collaborative |date=January 2024 |url=https://www3.weforum.org/docs/WEF_Regionalized_Vaccine_Manufacturing_Collaborative_2024.pdf |access-date=23 October 2026 |via=Climate Insights Directory}}
BibTeX
@techreport{worldeconomicforum2024regionalized, author = {{World Economic Forum}}, title = {{Regionalized Vaccine Manufacturing Collaborative}}, institution = {World Economic Forum}, year = {2024}, month = jan, url = {https://www3.weforum.org/docs/WEF_Regionalized_Vaccine_Manufacturing_Collaborative_2024.pdf}, urldate = {2026-10-23}, note = {Indexed by Climate Insights Directory} }

Full text

Collected · Record updated